

Subject Index

A

- AAT, *see* Alpha-1 antitrypsin
AATD-deficiency states, 212
AAT Pittsburgh, 212
ABCA3 deficiency disorder, 247–249, 253–254, 258–259
 animal models, 254
 diagnosis, 256–257
 genetic basis and pathogenesis, 250–254
 lung histopathology findings, 254
 mutations, 147, 249–250, 252
 in infants, 256
 treatment options, 257
 symptoms and signs, 255–256
 in transporting lipids, 253
 treatment options for, 257–258
 See also Surfactant protein B (SP-B); Surfactants
ABCA3 protein expression, 251–252
ABCA3 variants, 256
ABPA, *see* Allergic bronchopulmonary aspergillosis
ACD, *see* Alveolar capillary dysplasia
ACE, *see* Angiotensin-converting enzyme
Acetylcholine, 40
Acquired PAP, 112
 risk for secondary infections, 119
Acquired tracheobronchomegaly, 234
Acrocyanosis, 137
Activation
 alternate chloride channel, 357
 angiotensin I and II, 51
 apoptosis, 151, 153
 Bcells, 280
 caspase 3, 152
 CD40 receptor, 374
 CFTR protein, 343, 345
 deregulated TGF-beta, 412
 dTOR, 90
 F508 CFTR, 358
 ETB receptors, 58
 genomic and non-genomic signaling pathways, 94
 immune, 412
 matrix metalloproteinases, 61
 MMP, 94
 mTOR, 90–91, 95
 neutrophils, 346
 nuclear transcription factor kappa B, 344
 p38 MAPK, p42/44 MAPK, and PI3K, 93
 phase, 179–180
 platelet, 194
 signaling cascades, 150
 T-cell, 281–282, 398, 402
 T-cell inhibition, 417
 TGF- β , 154, 228
 voltagegated (L-type) calcium channels, 62
Activin, 174–176
Activin receptor-like kinase 1 (*ALK1*), 55
Activin type II receptors (*ACVR2* and *ACVR2B*), 176
Acute ER stress, *see* ER stress
Acute glomerulonephritis, 282
Acute interstitial pneumonia (DAD), 134
Acute IPF exacerbation, 140
Acute respiratory distress syndrome, 248
Adenine nucleotide-binding cassette (ABC)
 protein, 340
 in genetic diseases, 252
ADMA, *see* Asymmetric dimethylarginine
Adrenomedullin, 67
AEC2, *see* Alveolar type II epithelial cells

- AEC dysfunction, 153
 Air–blood barrier, 154
 Airspace septation defects, 229
 Airway abnormalities, 234–235
 Airway infection, 308, 344, 346, 351
 Albinism, *see* Hermansky–Pudlak syndrome
Alcaligenes xylosoxidans, 351
 ALK1 mutations, 55
 ALK1 type I receptors, 176–177
 Allergic bronchopulmonary aspergillosis, 9, 350
 Allergic rhinitis, 9
 Alpha-1 antitrypsin (AAT/Alpha 1 proteinase inhibitor), 2, 21, 102, 155, 209
 antiprotease activity, 217
 asthma in, 216
 augmentation therapy, 217
 bronchiectasis, 216
 cirrhosis in, 217
 cleavage of, 214–215
 clinical lung disease with, 215–217
 clinical testing, 218
 indications for, 219
 COPD in, 213–217
 diseases associated with, 218
 efficacy of, 217
 elastase activity, 217
 forming complexes with molecules, 214
 genetic modifications, 212–213
 normal and deficiency alleles, 213
 indications for testing for deficiency, 219
 liver disease with, 217
 oxidized form, 214
 participation in pathogenesis of COPD, 215
 polymerized forms, 215
 polymers accumulation, within ER, 218
 posttranslational-modified molecular forms, 213–215
 protease inhibitory activity, 211, 217
 regulation, 210
 serum levels of, 210
 structure, 210–211
 synthesis, 209
 Alpha-interferon, 271, 282, 396–397
 Alport's syndrome, 276, 283
 Alstrom syndrome, 295
 Alternate chloride channel activation, 357
 Alternative clinical trial designs, 33
 Alveolar capillary dysplasia, 256
 Alveolar hemorrhage, 284–285
 See also Hemorrhage
 Alveolar macrophages, 114, 117–118, 120, 121, 124, 196–197, 248, 333, 373, 378
 Alveolar proteinosis, 147, 196, 254, 258
 Alveolar type II cells, 112, 134, 143–144, 151, 156, 191, 333, 335
 Alveolar type II epithelial cells, 248
 Ambrisentan, 65
 American Thoracic Society, 134
 Aminoarylthiazoles, 358
 Aminorex fumarate, 40
 AMs, *see* Alveolar macrophages
 ANCA, *see* Antineutrophil cytoplasmic antibody
 Anemia, 63, 118, 283, 285, 392
 Angiogenesis, 50, 177–178, 268–269
 doxycycline treatment and, 271
 dysregulation of, 179–180
 Angiomyolipomas, 89, 93, 95, 102
 Angiotensin, 231
 Angiotensin-converting enzyme, 392
 Anti-B-lymphocyte antibodies, 124
 Antigen tolerance regulation, 281–282
 Antiglomerular basement membrane antibodies, 9, 276
 Anti-glomerular basement membrane (anti-GBM) disease, *see* Goodpasture's disease
 Anti-neutrophil cytoplasmic antibody, 9, 218, 286
 Antiprotease activity, 217–218
 Apical pulmonary fibrosis, 233
 Apnea, 236
 Apoptosis, 50, 56, 102, 152, 153, 200, 214, 228
 ARDS, *see* Acute respiratory distress syndrome
 Arginine therapy, 67
 Arrhythmias, 42, 44
 Arterial-specific Alk1 expression, 180
 Arteriovenous malformations, 55, 167, 270
 classical telangiectasia and, 170
 Artery-specific genes, 180
Aspergillus, 9
 Aspirin, 198
 Asthma, 4, 8–9, 95, 215–216, 235, 259
 Asymmetric dimethylarginine, 67
 Ataxic breathing, 6
 Atelectasis, 284
 Atopy, 9
 Atrial septostomy, 66
 ATS guidelines, 141
 ATP-binding cassette (ABCA3), 247
 Auscultation, 6–7, 270, 283, 377
 Autoimmune diseases, 118, 288, 395
 Autoimmune disorders, 125, 411
 Autoimmune PAP, 113–114, 118, 122
 clinical course and presentation of, 119
 diagnosis, 119–122
 genetical basis of, 118
 GM-CSF therapy, 123–124
 radiographic findings, 119–120

- surfactant homeostasis disruption of, 117–118
therapy for, 122
See also Pulmonary alveolar proteinosis
- Autoimmunity, 62, 398, 409
- Autopsy, 40, 139, 234, 257, 332, 349
- Autosomal recessive disease, 153, 340
- Avastia[®], 272
- AVMs, *see* Arteriovenous malformations
- Ayerza's disease, 40
- Azathioprine, 142, 287, 415–416
- B**
- BAE, *see* Bronchial artery embolization
- BAL, *see* Bronchoalveolar lavage
- BAL analyses, *see* Bronchoalveolar lavage
- BALF, *see* Bronchoalveolar lavage fluid
- Bardet-Biedl syndrome, 295
- Barium esophagram, 7
- Basement membrane, 277
and collagen, 277
structure of, 278–279
- B cells, 280, 374, 398, 417
- Bence-Jones proteinemia, 214
- Benzo(c)quinolizinium (MPB), 358
- Bevacizumab, 180, 272
- BHD gene, 95
- Bias, 31, 35
ENG, 174
free of, 32
gender, 268
referral, 295
sources, 33, 34
- Bilateral hilar adenopathy, 392
- Biot's breathing, 6
- Birbeck granules, 370, 373
- Birt-Hogg-Dubé (BHD) syndrome, 95
- Bisaminomethylbithiazoles, 358
- Black heart disease, 40
- Bleeding diathesis, *see* Hermansky-Pudlak syndrome
- Bleomycin, 135, 153–154, 200, 412, 417
- Bleomycin-induced fibrosis model, 135
- BMPR2* gene, 52, 54, 59
- BMPR2* haploinsufficiency, 60
- BMPR2* receptor, 52, 59
- BMPR2* mutations, 42, 53–55, 68
- BMPs, *see* Bone morphogenic proteins
- BNP, *see* B-type natriuretic peptide
- Body mass index (BMI), 351
- BOLD, *see* British orphan lung disease
- Bone morphogenic proteins, 59–60, 175–176
- BOOP, *see* Bronchiolitis organizing pneumonia
- BPOLD, *see* British pediatric orphan lung disease
- Bradypnea, 6
- Breathlessness, 4, 134, 144
- British orphan lung disease, 2
- British pediatric orphan lung disease, 2
- Bronchial artery embolization, 351
- Bronchial hyperreactivity, 235
- Bronchiectasis, 9, 138, 215–216, 234, 307–308, 312–314, 339, 347, 351, 410
- Bronchiolectasis, 138
- Bronchiolitis organizing pneumonia, 413
- Bronchoalveolar lavage, 140, 142, 197, 256, 259, 380, 392, 398, 399
- Bronchopulmonary dysplasia, 145
- Bronchoscopy, 7–9, 120, 122–123, 380, 391–392
- BTNL2* gene, 402
- B-type natriuretic peptide, 67
- Butyrophilin-like 2 (*BTNL2*) gene, 402
- C**
- Calcium channel-blocking agent, 64
- Calcium phosphate microliths, 325, 329, 331, 334
- Calnexin/calreticulin cycle, 150
- Cardiac rhabdomyomas, 89
- Cardiopulmonary exercise testing, 8
- Case-control designs, 35
See also Rare lung diseases
- Cauterization, 100
- CD1a, 373
- CD4:CD8 ratio, 380, 396
- CD4+ cells, 395
- CD8+ cells, 395
- CD4 count, 394–396
- CD4 lymphocytes, 394, 396
- CD8 lymphocytes, 394
- CD40 receptor, 374
- CD34 staining, 271
- CD4+ T cells, 399, 401
- Cellular pneumonitis, of infancy, 147
- Cerebral hemorrhage, 332
- CF, *see* Cystic fibrosis
- CF chromosomes, 340
- CFLD, *see* CF-related liver disease
- CFRD, *see* Cystic fibrosis-related diabetes
- CF-related liver disease, 353
- CFTR, *see* Cystic fibrosis transmembrane conductance regulator
- CFTR correctors, 358–359
- CFTR deficiency, 339–340, 344–348
pathophysiology of lung tissue destruction
in, 347
See also Cystic fibrosis
- Cftr* gene, 340

- CFTR mutations
 classes of, 342–343
 $\Delta F508$ mutation, 340, 348
 frequency of, 340
 heterozygote carriers of, 354
 potentiators, 358
See also Cystic fibrosis
- Chediak–Higashi syndrome (CHS), 198
See also Hermansky–Pudlak syndrome (HPS)
- Chemical pleurodesis, 101
- Chemokines, 142, 374, 411–412
- Chest CT scanning, 7–8, 86, 96–97, 284, 327–330, 378, 391
- Chest discomfort, 4–5
- Chest imaging, 3, 5, 7–8, 136–139, 198, 285, 390, 394
- Chest pain, 5, 43, 95, 118, 270, 376
- Chest X-ray, 3–4, 7, 86, 137, 143–144, 284–285, 326–327, 332, 377, 390–391, 394
- Cheyne–Stokes respirations, 6, 8
- Children with ABCA3 deficiency, 255–256
- Child with SP-B deficiency, 255
- Chlamydomonas reinhardtii*, 295
- Chlorodeoxyadenosine, 381
- Cholesterol, 248
- Chronic obstructive pulmonary disease, 4–5
- Chronic pneumonitis of infancy (CPI), 147
- Chronic thromboembolic pulmonary hypertension (CTEPH), 47
- Chylothorax, 101
- Chylous ascites, 95
- Chylous effusion, 9, 86, 95, 101
- Cigarette smoke, *see* Smoking
- Ciliopathies, 295
- Cincinnati Angiomyolipoma Sirolimus Trial, 101
- Cirrhosis, 217
- Clinical classification schema, 41
- Clinical manifestations
 AAT deficiency (AATD), 209, 212–213
 anti-glomerular basement disease, 283–284
 cystic fibrosis (CF), 339, 347, 351
 familial pulmonary fibrosis, 133, 142
 Goodpasture’s syndrome, 275
 HPS-2, 192–193
 immune reconstitution inflammatory syndrome, 395
 interstitial lung diseases (ILDs), 136
 primary ciliary dyskinesia (PCD), 306–307
 pulmonary alveolar microlithiasis (PAM), 326
 SP-C mutations associated with ILD, 143
 sarcoidosis, 390, 396–397
 scleroderma, 411
 TSC, 89
See also specific disorders
- Clinical trials, rare diseases, 32, 34, 88, 101, 103, 217, 313, 416
 designs, 32–34
 sources of bias, 33–34
 study designs hierarchy, 34–37
See also Rare lung diseases
- Clubbing, 96, 137, 143–144, 255, 351, 412
- Collagen, 277–279
See also Type I collagen; Type IV collagen
- Complementarity determining region 3 (CDR3), 399
- Computed tomography, 7, 119, 156, 413
- Congenital alveolar proteinosis, 254
- Congenital diaphragmatic abnormalities, 237
- Congenital PAP, 112, 118
- Congestive heart failure, 8
- Connective tissue disease–pulmonary associations, 22
- COP, *see* Cryptogenic organizing pneumonia
- Cor pulmonale, 137, 237–238, 270, 381, 412
- Corticosteroids, 140, 258, 351, 381, 393
- Cough, 4, 95, 144
- COX-2, in ECs, 181
- Craniofacial abnormalities, 227
- C-reactive protein (CRP), 67
- CREST syndrome, 413
- Crohn’s disease, *see* Hermansky–Pudlak syndrome
- Cross-over designs, 35
- Cryptogenic antigens, 280
- Cryptogenic organizing pneumonia, 134
- CSF2 mutations, 114
- CTLs, *see* Cytotoxic T lymphocytes
- Cutaneous–pulmonary associations, 13
- Cutis laxa, 233
- Cyanosis, 40, 119, 143, 156, 349
- 3′–5′-Cyclic adenosine monophosphate (cAMP), 64
- Cyclin-dependent kinase 1 (CDK1), 91
- Cyclophosphamide, 140, 381
- Cyclosporine, 140
- Cystic fibrosis, 5, 102, 295, 339
 cancer risk, 354
 CFTR mutations, 342–343
 pathophysiology of lung tissue with, 347
 clinical presentation, 349–351
 common manifestations of, 351
 lung infection, 350
 radiological manifestations, 350–351
 respiratory symptoms, 349
 current therapy for, 355–357
 cystic fibrosis-related diabetes, 352
 diagnosis, 354–355
 distal intestinal obstruction syndrome (DIOS), 353

- gastroesophageal reflux, 352
 hepatobiliary disease, 352–353
 high frequency of osteoporosis, 354
 hypersecretion of mucins, 346
 incidence of, 340
 infertility, 354
 intestinal manifestations, 353
 lipid abnormality and, 347–348
 liver and gall disorders, 352–353
 MBL2 gene expression, 343
 molecular pathogenesis of, 342–348
 nutritional concerns, 351–352
 osteoporosis, 354
 pancreatic insufficiency, 352
 pathogenesis, 342
 pharmacological approaches, 357–359
 resting energy expenditure, 351
 transgenic mouse model of, 348
 transmembrane conductance regulator, 155
 treatment for
 lung therapy, 355–356
 gastrointestinal therapy, 356–357
 Cystic Fibrosis Foundation, 355, 358
 Cystic fibrosis-related diabetes, 352
 Cystic fibrosis transmembrane conductance regulator (CFTR), 339, 341
 See also CFTR mutations
 Cystic lesions, 373
 Cystic lung disease, 234
 Cystic lymphangiomyomas, 97
 Cytokines, 112, 115, 117, 135, 174, 197, 215, 229, 281, 374–375, 393, 398, 401, 411
 Cytoplasmic phospholipase (*Cpla2*), 135
 Cytotoxic T lymphocytes, 192
- D**
- Dendritic cells, 370, 373–374
 Denufosal, 357
 Desmopressin (DDAVP), 198
 Desquamative interstitial pneumonitis, 134, 147, 254, 372
 Diagnosis, 2–3
 Diaphragmatic hernia, 237
 Diarrhea, 66
 Diffuse alveolar fibrosis, 134
 Diffuse interstitial lung disease, 410
 Diffuse parenchymal lung disease, 136
 Diffuse scleroderma, 413
 Diffusing capacity for carbon monoxide, 8, 101–102, 124, 139, 197, 379, 392, 413, 415
 Digital clubbing, 119, 255, 270
 DIOS, *see* Distal intestinal obstruction syndrome
- DIP, *see* Desquamative interstitial pneumonitis
 Dipalmitoylated phosphatidylcholine (DPPC), 248
 Distal intestinal obstruction syndrome, 353
 Diuretics, 63
 Digoxin, 63
 Dizziness, 199
 DLCO, *see* Diffusing capacity for carbon monoxide
DNAH5, 293–294, 296–299, 301, 311–312
DNAI1, 293–294, 296–297, 311–312
 Doppler echocardiography, 8
Drosophila melanogaster, 88
 Drug-induced pulmonary disorders, 3
 dTOR (*Drosophila* target of rapamycin), 90
 Duramycin, 357
 Dyspepsia, 66
 Dyspnea, 4, 40, 43, 95–96, 103, 118, 140, 143, 376, 381, 412
- E**
- Early endosome antigen (EEA)-1-positive vesicles, 151
 EBUS, *see* Endobronchial ultrasound
 Echocardiogram, 96
 Echocardiography, 8
 ECMO, *see* Extracorporeal membrane oxygenation
 Ectopia lentis, 225
Efnb2/Ephb4 genes, 180
 Ehlers–Danlos syndrome (EDS), 233, 235
 E66K mutation, 151–152
 Elastase, 61
 Elastin, 232
 Embolic cerebrovascular accidents (CVA), 169
 Embolization, 100
 Emphysema, 98, 102, 229–230, 373
 ENaC inhibitors, 357
 Enactin, 277
 Endobronchial ultrasound, 9, 392
 Endocrine/reproductive–pulmonary associations, 25–26
 Endoglin (*ENG*), 55, 172–173, 175
 Endoplasmic reticulum, 145
 mutants, retained in, 252
 protein folding in, 148–150
 Endothelial cell proliferation, 50
 Endothelial dysfunction, 56
 Endothelial nitric oxide synthase (eNOS), 57, 180–181
 Endothelin, 58, 65
 Endothelin-1 (ET-1), 56, 65–67
 Endothelin receptor antagonists, 65–66
 ENG/ALK1 ligands, 177
 ENG protein, 172
 eNOS/Hsp90 association, 181
 eNOS uncoupling/Cox2, 180–181
 Enzyme-linked immunoassay (ELISA), 285

- Eosinophilic granulomas, 370, 372
- Epidemiology
- CFTR mutation, 340
 - Goodpasture's syndrome, 282
 - HPS, 190
 - LAM, 88–90
 - PAH, 41–43
 - PAP, 114–115
 - PAM, 326
 - PCD, 294
 - PCH, 268
 - PiZ AATD, 212, 216
 - pulmonary LCH, 371
 - sarcoidosis, 390, 395
 - scleroderma, 409–410
 - surfactant deficiency disorders, 249–250
 - See also* specific disorders
- Epistaxis, 55, 194
- Epithelial-to-mesenchymal transition (EMT), 154–155
- Epithelium, 307, 339, 375
- airway, 228, 293, 345
 - alveolar, 112, 134
 - ciliated, 311
 - corneal, 209–210
 - intestinal, 209
 - retinal pigment, 200
 - respiratory, 309
- Epoprostenol, 65
- ER-associated degradation (ERAD), 148
- ER degradation-enhancing α -mannosidase-like protein (EDEM), 150
- Erlotinib, 416
- ER quality control receptor, 150
- ER, *see* Endoplasmic reticulum
- ER stress, 150–153, 155
- Erythema nodosum, 392
- ESTAT-6 protein, 402
- Estrogen receptor (ER), 93, 98
- ET_A receptor antagonist, 66
- Etoposide, 381
- E3 ubiquitin ligase, 150
- European Respiratory Society, 134
- Eustachian tube, 308–309
- Extracellular-signal-regulated kinases 1 and 2 (ERK1/2), 410
- Extracorporeal membrane oxygenation, 249
- F**
- Facial angiofibromas, 89
- Factorial designs, 35
- Familial hypocalciuric hypercalcemia, 135
- Familial pulmonary arterial hypertension (FPAH), 39, 41
- BMPR2* mutations in, 54, 68
 - NIH study, 51
 - pathology of vascular lesions in, 50
 - pathways and factors implicated in, 56
 - See also* Pulmonary arterial hypertension
- Familial pulmonary fibrosis, 136, 147
- characteristics, 141
 - clinical manifestations, 142
 - contrast to IPF, 142
 - histopathology, 142–143
 - radiographic imaging, 142
 - See also* Idiopathic pulmonary fibrosis
- FBN-1* gene, 225
- FEV1/FVC ratio, 382
- Fibrillin, 225, 227, 230, 237, 240
- Fibrillin-1, 227–230, 232
- Fibrillinopathies, TGF β signaling role in, 225
- Fibrosis, 58, 102, 134–135
- role of AEC dysfunction/apoptosis in pathogenesis, 153
 - See also* Cystic fibrosis; Idiopathic pulmonary fibrosis; Pulmonary fibrosis
- Fibrotic lung diseases, 135
- Flagellar axoneme, 296
- Flavones, 358
- Fluorescence in situ hybridization (FISH), 97
- Fluorodeoxyglucose, 8
- Fluoroscopy, 7
- Folliculin, 95
- Forced vital capacity, 101, 139, 199, 349, 392, 414, 416
- FPAH, *see* Familial PAH
- FVC, *see* Forced vital capacity
- G**
- GAP proteins, 90
- Gastroesophageal reflux, 352
- Gastrointestinal–pulmonary associations, 19–20
- Gastrointestinal therapy, 356–357
- Gaucher disease, 135
- GDF, *see* Growth and differentiation factor
- Gefitinib, 416
- Gelatinase B (MMP-9), 215
- Gene mutations, 52, 68, 89, 210, 342–343, 345
- See also* Mutations
- Gene replacement therapy, 258
- Gene therapy, 357
- Genetic basis, of diseases, 190, 248
- congenital PAP, 118
 - cystic fibrosis, 339–340, 342
 - HHT, 171

HPS, 190
 LAM, 90
 MFS, 226
 PCD, 295, 314
 sclerosis, 410–411
 surfactant deficiency disorders, 250
 Genetic mutations, 9
 Genetic testing, limitation, 257
 Genotype–phenotype correlation
 in HHT, 171, 174
 in *HPS1*, 197
 Germline mutations, 89
 Glomerulonephritis, 276
 α -Glucosidase inhibitor miglustat, 358
 Glycoproteins, 60, 115, 175, 209, 226, 340–341,
 345, 376
 phenol-rich, 376
 Glycosylation, 150
 GM-CSF, *see* Granulocyte/macrophage
 colony-stimulating factor
 GM-CSF autoantibodies, 113, 117–118
 GM-CSF receptor β chain, 118
 GM-CSF signaling, 113, 117–118
 GM-CSF therapy, 123–124
 GN, *see* Acute glomerulonephritis
 GnRh agonists, 101
 Goodpasture's syndrome, 275–276
 antibodies against
 α 3[IV] chain, 281
 N terminus of NC1, 280–281
 antigenic determinants, 279
 antigenic tolerance, regulation, 281–282
 basement membrane, 277
 clinical manifestations, 283–284
 and collagen biochemistry, 277
 cryptogenic antigens, 280
 epidemiology, 282–283
 E_A epitope of GP antigen, 281
 evaluation, imaging, 284
 genetic susceptibility, 282
 history, 276–277
 immune responses, 280–282
 lab studies, 285
 male predilection for, 282
 α 3. α 4. α 5 NC1 hexamer, 280
 pathogenesis, 279
 pathology, 284–285
 prognosis of patients, 287
 renal manifestations, criterion for,
 282–283
 role of Th1 response, 281
 serological assays and therapies, 285–287

G protein-coupled receptor (GPCR)
 pathway, 64
 Graham Steell murmur, 44
 Granulocyte/macrophage colony-stimulating factor,
 114, 374
 Granuloma, 372, 393, 400–402
 Groupe d'Etudes et de Recherche sur les Maladies
 Orphelines Pulmonaires (GERM"O"O"O"), 2
 Growth and differentiation factor, 174–175
 Growth factors, 58, 61, 92, 142

H

HAART, *see* Highly active anti-retroviral therapy
Haemophilus influenzae, 308
 Hamartin, 91
 Hamartomas, of skin follicles, 95
 Hamman–Rich disease, 144
 Ha-Ras, signaling protein, 410
 Heat-shock protein-70 (HSP70), 214
 Hemangioendotheliosis, 270
 Hematologic–pulmonary associations, 28
 Hematuria, 283, 287, 416
 Hemolytic anemia, 118
 Hemophagocytic lymphohistiocytosis, 197
Hemophilus influenzae, 350
 Hemoptysis, 4, 95, 118, 270–271, 276, 283, 351,
 376, 412
 Hemorrhage, 8, 167, 169–170, 194, 276
 Hemosiderosis, 270
 Hemothorax, 271
 Hepatitis C, 396–397
 Hepatitis viruses, 9
 Hereditary haemorrhagic telangiectasia (HHT), 55,
 167–181
 animal models for, 177–178
 clinical features, 167–169
 expression, variable, 170
 gene mutations, 172–174
 ACVRL1 (ALK1), 173–174
 ENG (Endoglin), 172–173
 MADH4 (SMAD4), 174
 genes and loci, 172
 genetic basis of, 171
 genotype–phenotype correlations, 174
 implicated roles, of ENG and ALK1, 178–181
 lung disease in, 168–169
 manifestations of, 168
 pulmonary hypertension in, 169–170
 structural basis, 170–171
 microscopic appearances of, 171
 typical manifestations of, 168
 See also Mutations

- Hermansky–Pudlak syndrome, 135, 153, 189–190
 albinism, 189, 191, 194
 associated animal models, 190
 clinical manifestations, 194–197
 bleeding diathesis, 194
 hemophagocytic lymphohistiocytosis, 197
 inflammatory bowel disease, 194
 interstitial lung disease, 195–197
 desmopressin (DDAVP), 198
 diagnostic approaches, 197–198
 biochemical and immunoblotting assay, 198
 disease models, 199–201
 model systems yeast and *drosophila*, 199
 mouse models, 200
 epidemiology, 190
 genetic loci associated with, 190
 genotype–phenotype correlations, 197
 medications and platelet transfusions, 198–199
 platelet dysfunction, 189, 191
Rab38 gene role, 200
 subtypes and genetic etiologies, 190–192
 heterozygotes, 194
 HPS-1 to 8 subtypes, 192–194
- Heterotaxy, 294, 301, 305–306, 309
- HHT, *see* Hereditary hemorrhagic telangiectasia
- Highly active anti-retroviral therapy, 395–396
- High-resolution thin section computed tomography, 7, 97, 99, 101, 137–138, 195–196, 198, 377–379, 413, 415
- Histiocyte Society and the American Histiocytosis Association, 370
- Histiocytic syndromes, 370
- Histiocytosis X, 370
- Histone deacetylase (HDAC) inhibitor, 155
- Historical controls, 31–37
See also Clinical trials
- HIV-associated sarcoidosis, 395
- HLH, *see* Hemophagocytic lymphohistiocytosis
- HMB-45, monoclonal antibody, 92, 98
- HMG-CoA reductase inhibitors, 68
- HPS, *see* Hermansky–Pudlak syndrome
- HRCT, *see* High-resolution thin section computed tomography
- hTERT* gene, 135
- hTR* gene, 135
- 5-HTT gene promoter, 55
- 5-HTT polymorphisms, 55
- Human herpes virus 8 (HHV-8) infection, 61
- Human immunodeficiency virus 1 (HIV-1) infection, 61
- Human *SFTPC* mutations, 148
- Hydrocephalus, 295
- Hydroxychloroquine, 155
- 7 α -Hydroxylase, 215
- 5-Hydroxytryptamine, 54, 59
- Hypercalcemia, 377
- Hyperphosphorylation, 91
- Hyperpnea, 6
- Hypersomnolence, 236
- Hypotonia, 237
- Hypoxemia, 134, 139, 168
- Hypoxia, 40, 50, 58, 60, 63, 68, 120, 270, 308
- I**
- Ibuprofen, 198, 356
- Idiopathic interstitial lung disease, 133–134, 373, 412
- Idiopathic interstitial pneumonias, 152
 categories, 134
 SFTPC mutations, 149, 151–152
 SP-C mutations associated with, 146–148
 molecular pathogenesis
 ER-associated degradation (ERAD), 148–150
 ER quality and UPR, 150–151
 ER protein folds, 148
 human *SFTPC* mutations with IIP, 148–149
See also Surfactant protein C (SP-C)
- Idiopathic PAP, 112–113, 117
- Idiopathic pulmonary arterial hypertension (IPAH), 39, 41
BMPR2 mutations in, 54
 clinical recommendations, 54
 genetic counseling, 54
 human herpes virus 8 in, 50
 NIH study, 51
 pathology, of vascular lesions in, 50
 pathways, and factors implicated in, 57
 severe pulmonary arteriopathy, 50
See also Pulmonary arterial hypertension
- Idiopathic pulmonary fibrosis, 2, 134, 141–142, 198, 373, 411–412
 clinical manifestations, 137
 corticosteroids or immunosuppressive agents
 effects, 140
 gas exchange, 139
 imaging studies, 137–139
 interferon- γ 1b, 140
 natural history of, 140
 pathology, 139–140
 prevalence, 136
 pulmonary function testing, 139
- Ifn- γ* gene, 137
- IgE levels, 9
- IIPs, *see* Idiopathic interstitial pneumonias
- ILD, *see* Diffuse interstitial lung disease
- ILDs, *see* Interstitial lung diseases

- Iloprost, 65
 Imatinib, 68, 416
 Immune reconstitution inflammatory syndrome, 394
 Immunodeficiency, 198
 Immunomodulation, 112
 Immunosuppression, 258, 286, 313
 Immunosuppressive therapy, 286
 Indirect immunofluorescence, 285
 Infertility, 305–306, 309, 354
 Inflammation, 7, 61, 134–135, 175, 196–197, 210, 227, 281, 314, 346, 351–352, 393, 409, 412
 Inflammatory bowel disease, *see* Hermansky–Pudlak syndrome
 Infliximab, 199
 Inhaled bronchodilator therapy, 356
 Interferon-gamma (IFN- γ), 103, 394, 398
 Interferon- γ 1 β , 140
 Interleukin-2 (IL-2), 394, 398
 International Federation of Marfan Syndrome Organizations (IMSFO), 240
 Interstitial lung diseases, 4, 7–8, 134–136, 141–142, 152, 195–197, 248–249, 372–373, 379, 381
 diffuse, 410
 with HPS-1/HPS-4, 195
 and mutations in SP-C, 143–145
 prognostic implications of, 415
 risk of, 197
 scleroderma, 411–412
 See also Hermansky–Pudlak syndrome ; Surfactant protein C (SP-C)
 Intrathoracic angiomyomatous hyperplasia, 86
 IPAH, *see* Idiopathic pulmonary arterial hypertension
 IPF, *see* Idiopathic pulmonary fibrosis
 Ischemic necrosis, 237
 I73T mutants, 152
- J**
 Japanese Ministry LAM Registry, 86
 Joubert syndrome, 295
 Jun gene, 93
- K**
 Kallikrein 3, 214
 Kaposi's sarcoma lesions, 50
 Kartagener syndrome, 294, 307, 309
 Kyphoscoliosis, 237
 Kyphosis, 6, 238
- L**
 L allele, 55
 LAM, *see* Lymphangioliomyomatosis
 Lamellar body membranes (LBM180), 251
 LAM Foundation Pleural Disease Consensus Group, 99
 Laminins, 277
 LAM lesions, 86, 98
 Langerhans' cell histiocytoses, 98, 370
 See also Pulmonary Langerhans' cell histiocytosis
 Langerhans' cells, 98, 373–376, 380
 L-arginine, 57
 LCH, *see* Langerhans' cell histiocytoses
 LDH levels, 9
 Leiomyomatosis, 86
 Leukocyte mobilization, 117
 LIP, *see* Lymphocytic interstitial pneumonia
 Lipoproteinosis, 112
 Lipoxigenase (5-LO), 135
 Löfgren's syndrome, 390, 393, 400
 LOH, *see* Loss of heterozygosity
 Losartan, 231
 Loss of heterozygosity, 89
 L188Q mutant, 151
 Lung biopsies, 7, 49, 121, 142, 144, 230, 257, 285, 330, 332, 392, 413, 415
 Lung cysts, 95
 Lung disease, in HHT, 168–169
 Lung disorders diagnose, and organs associated
 pulmonary associations with, 3–6
 connective tissue disease, 15–16
 cutaneous, 13–15
 endocrine/reproductive, 25–26
 gastrointestinal, 19–20
 hematologic, 28
 ophthalmologic, 15–18
 otorhinolaryngeal, 18–19
 metabolic disorders, 28–29
 neurologic, 26–27
 renal, 23–24
 Lung fibrosis, 135, 156, 229, 412
 See also Fibrosis
 Lung function, 8
 studies, in MFS, 231
 Lung histopathology, in HPS, 196
 Lung therapy, 355–356
 Lung transplantation, 90, 102–103, 139, 199, 258, 268, 271, 333, 349, 381, 416
 Lung volumes, 8
 Lymphadenopathy, 100
 Lymphangiomyomas, 100
 Lymphangiectasis, 270
 Lymphangiogenesis, 92, 98
 role in LAM pathogenesis, 92
 Lymphangioliomyomas, 95

- Lymphangioliomyomatosis, 2, 86
 cell of origin of, 92–93
 challenges, 103
 clinical presentation, 95
 cystic lung disease, associated with, 94–95
 diagnosis, 96–97
 management, 100–103
 and mTOR signaling cascade, 90–92
 occurrence in women, 93–94
 pathogenesis, 88
 benign metastasis model, 90
 pathology, 97–98
 histopathology, 98
 physical examination, 96
 physiology, 99
 radiology, 99–100
 abdominal CT, 100
 HRCT of lung, 99
 sources of epidemiologic data in, 86–88
 biopsy-documented LAM, 86, 88
 Japanese Ministry LAM Registry, 86
 LAM prevalence, 87
 NHLBI Registry, 86
 TSC-LAM affecting worldwide, 88
 sporadic, 89–90
 tuberous sclerosis complex-associated, 88–89
- Lymphangiomatous malformation, 86
- Lymphangiomyoma, 86
- Lymphangioliomyomatosis, 135
- Lymphangiopericytoma, 86
- Lymphocytes, 101, 400
See also T lymphocytes
- Lymphocytic interstitial pneumonia, 134
- M**
- Macrophage activation, 398
- Macrophage colony stimulating factor (M-CSF), 117
- Major histocompatibility complex (MHC), 282, 411
- Marfan lung, 231
- Marfan mice, 227–228
- Marfan's syndrome, 225
 airway abnormalities, 234–235
 animal models, 226–231
 adult emphysema, 229–230
 airspace septation defects, 229–230
 for fibrillin-1, 227–230
 mouse vs. human lung phenotype, 230–231
 for TGFb dysregulation, 229
 diagnosis of, 238–239
 frequency of prevalence, 226
 gene disorders in, 226
 lung and pleural abnormalities, 233–234
 management of, 239
 Marfan lung, translation of findings, 231
 fibrillin-1 deficiency, 231
 losartan studies, 231
 musculoskeletal, and developmental abnormalities,
 236–238
 pulmonary manifestations, 232
 related disorders and related genes, 233
 sleep disturbances, 235–236
 surgery, pulmonary considerations, 238
 TGFb, therapeutic target, 240
- Matrix metalloproteinases, 62, 96, 156
- Maxillary measurements, 236
- mean Pulmonary arterial pressure (mPAP), 42
- Meckel-Gruber syndrome, 295
- Melanocytic transcription factor (MITF), 92
- Metabolic disorders–pulmonary associations,
 28–29
- Metastasin-1 (Mts-1), 61
- Metastasis, 88, 90, 92
- Methicillin-resistant *Staphylococcus aureus*
 (MRSA), 351
- Methotrexate, 381
- MFS, *see* Marfan syndrome
- Microliths, 326, 329–332, 334
- Missense mutations, 251
- Mitral stenosis, 40
- MMPs, *see* Matrix metalloproteinases
- Moli1901, 357
- Monocrotaline, 63
- Mouse models, of PCD, 301–303
Dpcd-and *Poll*-deficient mouse, 304
Foxj1/Hfh4-deficient mouse, 305
Hydin-deficient mouse, 305
lrd-deficient mouse, 303–304
Mdhc7-deficient mouse, 305
Mdnah5-deficient mouse, 303
Pcdp1-deficient mouse, 304
Pf16/Spag6-deficient mouse, 306
Pf20/Spag16-deficient mouse, 306
Spag6/Spag16L double knockout mouse, 306
Tektin-t-deficient mouse, 305
See also Primary ciliary dyskinesia
- mRNA splicing, 257
- mTOR
 activation, 90, 95
 functionally distinct complexes, 90
 inhibitor therapy, 102
 Raptor complex 1 pathway (TORC1), 91
 –riCTOR binding, 95
 signaling pathway, 91
- Mucins, 345

- Mucus, 293–294, 302, 304, 308–309, 313, 339, 341, 345–347, 350–351, 353, 356
- Mucociliary clearance, 293
- Multicenter International LAM Efficacy of Sirolimus Trial (MILES), 102
- Multidetector spiral computed tomography, 7
- Multisystem LCH, 371
- Muscle hypoplasia, 227
- Mutations
- 121ins2 mutation, 251
 - in AAT gene, 210
 - in *ABCA3*, 153, 249, 252, 256, 259
 - in *ACVRL1* (ALK1), 172–173
 - affecting *Cftr* gene, 340, 342–343, 348, 358
 - in *Alk1*, 179–180
 - altering *BMPR2* coding, 52
 - in *AP3β1* gene, 192
 - in Ap3b1 subunit of AP-3, 192–193
 - in *BLOC1*, 194
 - in BRICHOS domain, 152
 - in *CFTR*, 299
 - combinatorial mutations of BLOCs and/or AP-3, 200
 - of ΔF508, 340–341
 - in *DNAH5*, 311
 - in *DNAH11*, 299, 304, 311
 - in *DPCD*, 304
 - in *ENG* and *ALK1*, 52, 172
 - in *FBN-1* gene, 225
 - in fibrillin, 237
 - in HHT genes, 170, 172
 - in *HPS1*, 192–194
 - in *HPS3*, 190, 197
 - HPS-2 with mutation in *AP3β1*, 199
 - of human ortholog of dysbindin (DTNBP1), 193
 - in *lbrk*, 201
 - in *MADH4*, 171–172, 174
 - at N138T and N186S, 144
 - of *OFD1*, 300
 - in PCD
 - of *DNAH5* gene, 298
 - of *DNAI1* gene, 297
 - predispose to IPAH, 51
 - in *Rab38*, 200
 - in *RPGR*, 295, 300
 - in *SFTPB*, 248, 256
 - in *SFTPC*, 143, 146, 152–153, 155
 - of *SLC34A2* gene, 333
 - in *SPAG16* or *SPAG6*, 306
 - in SP-B and *ABCA3* genes, 249–250
 - TSC1/TSC2* mutations, 90
 - in *Tsk1*, 412
 - in two genes (*DNAI1* and *DNAH5*), 294
 - in type IV collagen gene, 276
- Myc gene, 93
- Mycobacterial catalase-peroxidase (mKatG), 402
- Mycobacterium tuberculosis*, 9
- Mycophenolate mofetil, 417
- Mycoplasma pneumoniae*, 268
- Myelodysplastic syndrome, 382
- Myopathy, 237
- N**
- N*-acetyl cysteine, 140
- Narcolepsy, 8
- Nasal epithelial biopsies, 10
- Nasal nitric oxide (nNO), 295
- levels, 310–311
 - screening tests, 295
- Nasal polyps, 351
- National Heart, Lung and Blood Institute (NHLBI), 41, 86
- National Human Genome Research Institute, 198
- National Institutes of Health (NIH), 41
- National Institutes of Health Office of Rare Diseases (ORD), 2
- National Organization for Rare Diseases, 2
- Neonatal pneumonia, 308
- Neonatal respiratory distress, 307
- Nephrectomy, 100
- Nephronophthisis, 295
- Neurofibromatosis, 135
- Neurologic–pulmonary associations, 26–27
- Neutral lipids, 248
- Neutrophils, 117, 215
- Newborn, 247, 252, 308
- period, 249, 255, 259
 - screening, 340, 344, 349, 354
 - tachypnea in, 312
 - transient tachypnea of (TTN), 256, 307
- New York Heart Association (NYHA), 42
- New York Heart Association functional classification of PAH, 43
- Nidogen, 277
- Niemann–Pick disease, 135
- Nitric oxide (NO), 57, 66
- Nitrites, 67
- N-of-1 designs, 35
- Noncollagenous proteins, 277
- Nonserine proteases, 211
- Non-specific interstitial pneumonia, 134, 142, 413
- Nontuberculous mycobacterium (NTM), 308
- NO synthase (NOS) enzymes, 57

- Notch–Delta downstream transcription factor (Gridlock), 180
 Notch ligand *Delta* (Dll4) gene, 180
 NSIP, *see* Non-specific interstitial pneumonia
 Null genes, 212
- O**
- Obstruction, of airflow, 5
 Obstructive sleep apnea (OSA), 5, 235
 Ophthalmologic–pulmonary associations, 15–18
 Oposonization, 112
 Organizing pneumonia (OP), 413
 Orphanet, 2
 Osler-Weber-Rendu disease, 10, 14
 Osler-Weber-Rendu syndrome, 14, 167
 Ossification, 331
 Osteoporosis, 333, 352, 354, 357
 Otitis media, 308
 Otorhinolaryngeal–pulmonary associations, 18–19
- P**
- PAH, *see* Pulmonary arterial hypertension
 PAH-related deaths, 42
 Palpation, 6
 PAM, *see* Pulmonary alveolar microlithiasis
 Pancreatic insufficiency, 352
 Panniculitis, 218
 Papanicolaou staining, 9
 PAP, *see* Pulmonary alveolar proteinosis
 PAP-like disorders, 112
 PAP syndrome, 113–114
 PASM, *see* Pulmonary artery smooth muscle cells
 PASM proliferation, 55
 PAVMs, *see* Pulmonary arteriovenous malformations
 PCD, *see* Primary ciliary dyskinesia
 PCH, *see* Pulmonary capillary hemangiomatosis
 PDGF, *see* Platelet-derived growth factor
 PEComas, 92
 Pectus excavatum (PE), 6, 236
 Percussion, 6
 Perivascular epithelioid cell tumors, 92
 Perlecan, 277
 Peroxisome proliferator-activated receptor gamma (PPAR γ), 67
 Persistent pulmonary hypertension of the newborn, 41
 PET scans, 8
 Phagocytosis, 117
 Phagolysosome fusion, 115
 Phase-contrast magnetic resonance (MR) imaging, 67
 PH associated, with disorders of respiratory system, 41
 4-Phenylbutyrate (PBA), 155, 358
 Phenylglycine, 358
 Phosphate transport, 333–334
 Phosphatidylglycerol (PG), 248
 Phosphatidylinositol 3-kinase (PI3K), 93
 Phosphodiesterase inhibitors, 66
 Phosphodiesterase-5 (PDE-5) inhibitors, 358
 Phospholipids, 248
 Phosphorylation
 binding BMPs to BMPRII receptors, 59
 degree of R domain, 341
 of p42/44 MAPK, 94
 of SMAD proteins, 175
 of tuberlin, 91
 Pigmentation, with HPS subtypes, 195
 PI3K inhibitor, 93
 PiMZ phenotypes, 217
 Pirfenidone, 140–141, 199, 201
 PiZ and PiSZ gene, 212
 See also Alpha-1-antitrypsin
 Plasmapheresis, 286
 Platelet-derived growth factor, 58, 67–68, 411, 416
 Platelet transfusions, 198
 Pleiotropism, 225–226
 Pleural complications, 100–101
 Pleural symphysis, 101
 Plexiform lesions, 49
 Pneumoconioses, 3
 Pneumothoraces, 381
 Pneumothorax, 6, 95–97, 100, 229, 233, 238, 349
 Polycystic kidney diseases, 295
 Polycystic liver disease, 295
 Polycythemia, 40
 Polymorphisms, 68
 for association with pulmonary fibrosis, 411
 G-945C in promoter of, 411
 in HLA family of genes, 402
 in serotonin, 54, 59
 in vasoactive mediators, 68
 Polymyalgia rheumatica, 118
 Polysomnography, 8
 Poly-ubiquitination, 150
 Potassium channel openers, 67
 Potassium channels, 67
 PPH, *see* Primary pulmonary hypertension
 Prednisone, 140, 271, 381, 415–416
 Premature termination codon, 358
 p70 ribosomal protein S6 kinase (p70S6K), 90
 Primary ciliary dyskinesia, 293–295
 challenges in, 294
 clinical manifestations of, 306–309
 diagnosis, 310–312
 ciliary function, assessment, 311
 electron micrographs, 310

- epidemiology, 294–295
- flagellar axoneme, schematic, 296
- genetics of, 295
 - DNAH5*, 296–299
 - DNAH11*, 299
 - DNAI1*, 296
 - linkage studies, 300
 - ODF1* and *RPGR*, 300
 - proteomics, 300
 - TXNDC3*, 299–300
- management principles for, 312–314
- mouse models for, 301–306
- mutations
 - of *DNAI1* gene in, 297
 - of *DNAH5* gene in, 298–299
- ODA defects, 297
- therapy, 314
 - and treatment, 312–314
- Primary pulmonary hypertension, 41, 51, 268–270
- Primary spontaneous pneumothoraces, 96
- Progesterone receptors, 98
- Progestins, 101
- Proliferating cellular nuclear antigen (PCNA), 98
- Prostacyclins, 57, 64–65
- Prostate-specific antigen (PSA), 214
- Proteasome dysfunction, 153
- Protein misfolding, 155
- Proteinuria, 283
- Pseudomonas aeruginosa*, 308
- Pseudomonas aeruginosa* elastase, 215
- Pseudomonas cepacia*, 350
- Pulmonary alveolar lipoproteinosis, 112
- Pulmonary alveolar microlithiasis, 325
 - diagnosis, 329–332
 - frequency of occurrence, 326
 - genes causing
 - autozygous segments, 335
 - population genetics, 335
 - SLC34A2*, mutation in, 333–334
 - therapies, 334
 - history and occurrence, 325–326
 - microscopic studies, 329–331
 - pathology, 329
 - prognosis, 332
 - radiologic studies, 328–330
 - scintigram, 328
 - signs and symptoms, 326–327
 - therapy, 332–333
- Pulmonary alveolar phospholipidosis, 112
- Pulmonary alveolar phospholipoproteinosis, 112
- Pulmonary alveolar proteinosis, 112
 - classification, 113
 - effective therapy for, 122–123
 - ELISA, 121
 - epidemiology, 114–115
 - immunological therapies, 125
 - molecular pathogenesis, 115
 - animal models, 115–116
 - disruption of surfactant homeostasis, 117
 - genetic basis of, 118
 - open lung biopsy in, 121
 - smoking associated, 114
- Pulmonary aplasia, 237
- Pulmonary arterial hypertension, 40–41
 - cell-based therapy with, 69
 - clinical assessment, 43
 - diagnostic testing, 44–45
 - physical examination, 44–45
 - clinical classifications development, 40–41
 - clinical history, 40
 - epidemiology
 - incidence, 42
 - natural history, 42
 - prognosis, 42
 - genetic factors, 68
 - interventional procedures, 66
 - pathobiology, 68
 - pathogenesis, 55
 - BMP2 mutations in, 52–54, 59–60
 - elastases, 61
 - endothelial dysfunction role, 56
 - endothelin (ET) family, 58
 - growth factors, 58
 - inflammation, 61
 - ion channels, 62
 - nitric oxide (NO) role, 57
 - prostacyclin, 57
 - Rho-kinase (ROK), 62
 - S100A4 (metastasin-1), 61
 - serotonin, 59–60
 - Smad signaling, 59
 - thromboxane (TXA₂), 58
 - TGF- β , 59
 - TN-C, 60
 - VIP, vasodilator, 60
 - pathology, 49–50
 - pharmacotherapies in, 67
 - presence confirmation, 48
 - timeline of diagnostic research, 41
- Pulmonary arterial pressures, 40
- Pulmonary arteriovenous malformations, 168–169
- Pulmonary artery smooth muscle cells, 59
- Pulmonary auscultation, *see* Auscultation

434 Subject Index

- Pulmonary capillary hemangiomas, 267
 - clinical information, 270
 - diagnosis, 270–271
 - histopathology revealing, 268
 - immunohistochemical analysis, 269
 - pathogenesis, 268–270
 - physical signs in patients with, 270
 - vs. PPH, 270
 - prevalence, 268
 - treatment for, 271–272
 - Pulmonary capillary hypertension, 271
 - Pulmonary circulation, 40
 - Pulmonary differential diagnosis, 10
 - Pulmonary diseases/conditions limited to lungs, *see* Lung disorders diagnose
 - Pulmonary disorders, 2–3
 - Pulmonary embolism, 270
 - Pulmonary fibrosis, 5, 137, 153, 233, 238, 270, 396, 411
 - animal models of, 153–155
 - highest risk for, 198
 - histopathology, 142–143
 - microarray analysis, of lung RNA, 142
 - mouse models of HPS develop, 200
 - patients with BLOC3 defects, 191
 - role of EMT in, 154–155
 - severity of, 197
 - Pulmonary function abnormalities, 238
 - Pulmonary function testing, 8, 139
 - Pulmonary hemodynamics, 40
 - Pulmonary hemorrhage, 276, 284–286
 - See also* Hemorrhage
 - Pulmonary hypertension, 8–9, 412
 - clinical classification, 40
 - current therapies for, 63–67
 - calcium channel-blocking agent, 64
 - conventional and targeted therapies, 63–66
 - etiology, evaluation of, 46
 - contrast CT finding, 48
 - pulmonary function testing, 47
 - radiographic testing, 47
 - role for MRI, 48
 - serologic and laboratory testing, 48
 - thromboembolic disease, evaluation, 47
 - in HHT, 169–170
 - plexiform lesion and, 49–50
 - See also* Pulmonary arterial hypertension
 - Pulmonary hypertensive (PH) diseases, 41
 - Pulmonary inflammation, 135
 - Pulmonary Langerhans' cell histiocytosis, 369
 - chest CT, 378
 - chest radiograph (CXR), 376–379
 - diagnosis of, 380
 - epidemiologic studies, 371
 - exercise limitation, 379
 - gross pathology, 372–373
 - bronchiolocentric lesions, 372
 - cystic lesions, 373
 - honeycombing, 372
 - lesional Langerhans' cells, 372
 - high-resolution CT scan of chest, 377–378
 - pathogenesis, 373–376
 - physical examination, 377
 - prognosis, 382
 - pulmonary function testing, 379
 - reactive polyclonal expansion in, 376
 - symptoms, 376–377
 - therapeutic intervention, 380–382
 - Pulmonary manifestations, 9
 - Pulmonary medicine, 2
 - Pulmonary pressures, 40, 43, 47
 - Pulmonary sarcoidosis, *see* Sarcoidosis
 - Pulmonary surfactants, *see* Surfactant
 - Pulmonary tuberculosis, 234
 - Pulmonary vascular resistance (PVR), 42
 - Pulmonary vasculature, in *Alkl*-deficient mice, 179
 - Pulmonary vasoconstriction, 40
 - Pulmonary veno-occlusive disease (PVOD), 270
 - Pulmonary venous hypertension, 41
 - Purified protein derivative (PPD), 9
 - Purine receptor agonists, 357
 - PU.1, transcription factor, 116
- ## Q
- Quinazoline VRT-325, 358
- ## R
- Radiographic imaging, 3
 - Raf/MEK/MAPK signaling cascade, 92
 - Randomized control trials, 36, 313
 - Rapamycin, 90, 92, 95, 102
 - Rare diseases, defined, 1–2
 - Rare lung disease, 2, 10, 294
 - Rare Lung Disease Consortium (RLDC), 2
 - Rare lung diseases, 2
 - alternative clinical trial designs, 33
 - clinical evaluations
 - imaging studies, 7–8
 - physical examination, 6–7
 - physiologic studies, 8–9
 - role of patient history, 3–6
 - clinical trial designs for, 32
 - randomized controlled trial, 32–33
 - bias, minimization of, 32–34

- study designs, hierarchy, 34–37
 - case–control designs, 35
 - concurrent controls, 34–35
 - cross-over, 35
 - factorial designs, 35
 - historical controls, 34
 - interim analyses, 36–37
 - N-of-1 trials, 35
 - randomized trials, 36
 - ranking and selection designs, 35–36
 - sample size, 35–36
 - Rare pulmonary diseases, 10–13
 - RDS, *see* Respiratory distress syndrome
 - Reactive oxygen species, 410
 - dependent lesions, 153
 - Recurrent respiratory infections, 9
 - REE, *see* Resting energy expenditure
 - Renal angiomyolipomas, 89, 95, 100
 - Renal cell carcinoma, 95
 - Renal–pulmonary associations, 23–25
 - Renal tumor, 101
 - Respiratory bronchiolitis (RB)-associated ILD, 134
 - Respiratory disorders, 3
 - Respiratory distress, 6
 - Respiratory distress syndrome, 144–145, 247–248, 256, 259
 - Respiratory failure, 143
 - due to PAM, 332
 - hypoxemic, 255, 257
 - in mature newborns, 249
 - mortality, 119
 - myopathy with, 237
 - neonatal, 151
 - pulmonary LCH progress to, 382
 - pulmonary vascular issues and, 237–238
 - scoliosis results in, 237
 - Respiratory history, 1, 3
 - See also* Rare lung diseases
 - Respiratory muscle strength, 8
 - Respiratory pattern, 6
 - Respiratory physical examination, 2, 3, 6–7, 43–44, 96, 136–137, 283, 326, 377, 412
 - Respiratory rate, 6
 - Respiratory sounds, 5
 - Respiratory symptoms, 3, 6, 143–144, 168, 255, 307, 349, 390
 - Respiratory syncytial virus (RSV), 152
 - Resting energy expenditure, 351
 - Reticulin staining, 271
 - Retinitis pigmentosa, 295
 - Rheb-Like protein (RLP), 90
 - Rheb protein, 90
 - Rheumatoid arthritis, 118
 - Rhinosinusitis, 308
 - Rho kinase inhibitors, 67
 - Rho-kinase (ROK/ROCK), 62
 - Right atrial pressure (RAP), 42
 - Right heart catheterization, 96
 - Right ventricle (RV) dysfunction, 57
 - Right ventricular failure, 42
 - Rituximab, 287
 - ROCK inhibitors, 63
 - ROCK signaling, 62
 - ROS, *see* Reactive oxygen species
- S**
- Sample size, 35–36, 300
 - S100A4 protein, 61
 - Sarcoid, 13–15, 18, 20–22, 389–397, 401
 - Sarcoidosis, 270, 389
 - associated with IFN therapy, 396–397
 - chest CT imaging, 391
 - chest X-rays, 390–391
 - diagnosis of, 392
 - and hepatitis C, 396–397
 - and HIV infection, 394–396
 - immunopathogenesis of, 400
 - inflammatory response in, 398
 - lab abnormalities, 392
 - natural history, 393
 - pathogenesis of, 397
 - etiologic antigens in, 402–403
 - genetic susceptibility to, 401–402
 - immune basis of, 398–401
 - pathology, 391
 - prevalence of, 390
 - pulmonary function studies, 392
 - respiratory symptoms, 390
 - therapy for, 391–394
 - TNF- α inhibition, 397
 - Schizosaccharomyces pombe*, 95
 - Scleroderma, 409
 - animal models, 411–412
 - BAL technique, 414
 - chest radiograph, 413
 - diagnostic approach, 415
 - histopathological pattern, 413–414
 - HRCT imaging, 414
 - incidence rate, 410
 - management, 415–416
 - pathogenesis of, 410–411
 - physical examination, 412
 - physiologic findings, 413
 - symptoms, 412

436 Subject Index

- Scleroderma (*Continued*)
 therapeutic modalities, 416–417
- Sclerosis, 40
- Scoliosis, 6, 238
- Screening CT scan, in women, 96–97
- Second hit mutation, 89
- Serologic testing, 9
- Serotonin, 54, 59–60
- Serotonin (5-HT) antagonists, 67
- Serotonin transporter (5-HTT) inhibitors, 67
- SERPINA1, *see* Alpha-1 antitrypsin (AAT)
- Serratia marcescens* metalloproteinase, 215
- Serum aminotransferases, 66
- Serum response factor (SRF), 94
- SFTPA1* and *SFTPA2* gene, 248
- SFTPC* gene, 143
- SFTPC* index mutation, 151
- SFTPC* mutations, 144, 147–149
 active TGF- β 1 and, 154
 associated with IIP, 149
 cell culture data, 151–152
 molecular pathogenesis
 ER-associated degradation (ERAD), 148–150
 ER quality and UPR, 150–151
 ER protein folds, 148
 type II cells adaptation, 152
 human *SFTPC* mutations with IIP, 148–149
 transgenic mouse data, 152
 treatment modalities, 155
 See also Idiopathic interstitial pneumonias
- Sildenafil, 66, 358
- Single-nucleotide polymorphism, 144, 250, 333, 335
- Sinusitis, 351
- Sirolimus, 101–102
- Sitaxsentan, 66
- Situs inversus, 299, 304–305, 307, 309–310
- Skin testing, 9
- S-LAM angiomyolipoma, 94
- Sleep apnea, 235
- Sleep disorders, 8–9
- Sleep disturbances, 235–236
- Smad3* gene, 135
- SMAD proteins, 175–176
- Smad signaling, 59–60
- Smoking, 42, 96, 114, 212, 240, 371, 373–374, 380–382
- Smoking-related lung disease, 371
- S-nitration, 214
- S-NO-AAT complex, 214
- Snoring, 5
- SNP, *see* Single-nucleotide polymorphism
- SP-B gene, 252
- SP-C^{L188Q} mutant, 151
- SP-C mutations, 146–148, 152, 156
 SP-C g Δ exon4 mutant, 151
 See also Surfactant protein C (SP-C)
- SP-C proprotein, 145–146
- Spirometry, 8, 99, 139, 284
- Splicing mutations, 251
- Spontaneous pneumothorax, 95, 233–234
- Sporadic idiopathic pulmonary fibrosis, 142–143
 See also Fibrosis
- Sporadic ILD, 147
- Sputum analysis, 9, 285
- Staphylococcus aureus*, 215, 308, 350
- Statins, 68
- Stenotrophomonas maltophilia*, 351
- Stridor, 5
- Subpleural bullae, 233
- Sudden death, 42
- Sulfonamide, 358
- Suppressor syndrome, 85–86
- Surfactant metabolic dysfunction disorders, 113
- Surfactant protein B (SP-B), 247–249
 deficiency, symptoms and signs, 255–256
 animal models used, 254
 diagnosis, 256–257
 epidemiology, 249–250
 in infants, 250–251, 254
 lung histopathology findings, 254
 gene encoding, results of mutations, 250–252
 treatment, 257–258
 See also ABCA3 deficiency disorder; Surfactants
- Surfactant protein C (SP-C), 136, 145
 mutations, associated with ILD, 143–148
 peptide components of, 145
 proprotein structure and function, 145–146
 See also Idiopathic interstitial pneumonias
- Surfactant protein D, 346
- Surfactant protein (SP)-A and SP-D, 112
- Surfactants, 112
 ABCA3 as candidate gene for, 252
 abnormal accumulation, 115–116
 accumulation, 112, 119
 analysis of BAL/tracheal aspirate fluid for, 256
 catabolism of, 112–113, 116
 clearance, disorder in, 113
 components of, 145
 composition, 112
 deficiency disorders, 247–249
 ABCA3 deficiency, *see* ABCA3 deficiency disorder
 genetic cause of deficiency, 249
 SP-B and ABCA3 genes mutations, 249–254

- SP-B deficiency, *see* Surfactant protein B (SP-B)
 therapy, 122
 disruption of homeostasis, 117
 dysfunction, 254
 genetically engineered mice expressing, 254–255
 GM-CSF administration and, 116, 123
 hereditary mutations and, 115
 histopathology findings of, 257
 homeostasis, disorders, 112–113
 classification, 113
 immunohistochemical stains for, 120–121
 importance of, 145
 inactivation, 247–248
 lipids, role, 248–249
 metabolism of, 333–334
 mutations and lung diseases
 in gene encoding, 136, 147
 peptide components of, 145
 phenotypes, of fatal surfactant deficiency, 250, 252
 production, disorders in, 118
 proteins
 mutations, 5
 role in metabolism, 147
 types, identified, 248
 pulmonary, 145, 247–248
 impaired secretion, 151
 replacement therapy, 258
 roles for
 ABCA3 family of transporters, 249
 alveolar macrophage and, 114, 124, 256
 targeted deletion of *Abca-3* in mice and, 153
 Suspected lung disease, diagnostic evaluation, 3
 SU5416 treatment, 63
 Swallowing study, 7
 Sweat chloride measurement, 9
 Syphilis, 40
 Systemic anti-inflammatory therapy, 356
 Systemic sclerosis, 410
- T**
- Tachypnea, 6, 134
 TBB, *see* Transbronchial lung biopsy
 TBLB, *see* Transbronchoscopic lung biopsy
 TBM, *see* Acquired tracheobronchomegaly
 TBNA, *see* Transbronchial needle aspiration
 T-cell receptor, 400–401
 T-cells, 61, 373, 380, 400, 402, 417
 TCR, *see* T-cell receptor
 TCRB genes, 399
 Telangiectasia, 5
 Tenascin-C (TN-C), 60
 Tetracycline, 255
 Tetrahydrobenzothiophene, 358
 TGF β binding proteins, 228
 TGF β dysregulation, 228–229
 TGF- β family signal transduction
 ALK1 receptor, 176–177
 ENG (CD105) glycoprotein, 175
 identity of ENG/ALK1 ligands, 177
 SMAD proteins, 175–176
 TGF- β pathway, 55
 TGFBR1, 233
 Th1 responses, 281
 Thoracentesis, 9
 Thoracic wall abnormalities, 8
 Thromboxane (TXA₂), 58
 T lymphocytes, 372, 375–376, 389, 397
 Tobacco glycoprotein, 376
 See also Glycoproteins
 TOBI[®], 356
 Tolazoline, 40
 TOR pathway, 95
 Toxoplasmosis, 395
 Tracheal collapse, 234–235
 Tracheal compression, 234–235
 Tracheomalacia, 234–235
 Transbronchial lung biopsy, 392
 Transbronchial needle aspiration, 392
 Transbronchoscopic lung biopsy, 380
 Transforming growth factor- β (TGF- β), 59–60,
 374, 416
 Transient tachypnea of newborn, 256
 Triglyceride level, 9
 Troponin T, 67
 TSC, *see* Tuberous sclerosis complex
TSC1 mutations, 90
TSC2 mutations, 89–90
 TSC/Rheb/mTOR pathway, 94
 TTN, *see* Transient tachypnea of newborn
 Tuberin, 91, 93
 Tuberous sclerosis, 135
 Tuberous sclerosis complex, 88–95
 Tubular myelin, 248
 Tumor necrosis factor-alpha (TNF α), 374, 398
 Tumor, 26, 92, 97, 100
 cells, 94
 epithelial, 103
 koenen, 13
 metastasis, 61
 renal, 24, 101
 stromal, 416
 suppressor protein, 50
 in TSC, 89–90
 types, 92
 vascular, 102

438 Subject Index

Tumor suppressor syndrome, 85, 89
Tunicamycin, 150
Type 17 helper T (Th17), 398
Type 1 helper T (Th1) cells, 398
Type 2 helper T (Th2) cells, 398
Type I collagen, 154, 232, 277
Type II cells, 153
 adaptation of, 152
Type II cytotoxicity, 153
Type IV collagen, 276–277
 structure of, 279
Tyrosine kinase inhibitors, 68

U

UACP, *see* Upper airway closing pressures
UIP, *see* Usual interstitial pneumonia
Ultrasound, 8, 97, 307, 353
UMD-Fbn1 database, 226
Unfolded protein response, 133, 150, 156
United Network for Organ Sharing, 102
Upper airway closing pressures, 235
UPR, *see* Unfolded protein response
UPR signaling pathway, 150
Ursodeoxycholic acid (UDCA), 357
US Multiple Cause of Death (MCO) mortality
 database, 136
Usual interstitial pneumonia, 134, 139

V

Vaccinations, 199
Vardenafil, 358
Vascular endothelial growth factor, 50, 58, 67, 180,
 269, 272

Vascular endothelial growth factor D, 92, 97
Vascular remodeling, 60–62, 68–69
 compounds, 50
Vascular repair, 68
Vasculitis, 276
Vasoactive intestinal peptide, 60
Vasoconstriction, 50
Vasodilators, 40
VEGF, *see* Vascular endothelial growth factor
VEGF-D, *see* Vascular endothelial growth factor D
VEGF receptor, 50
Video-assisted thoroscopic surgery, 10
Vinblastine, 381
VIP, *see* Vasoactive intestinal peptide
Viral infection, 61–62
Viral infections, 9, 395
Voltage-gated (L-type) calcium channels, 62
Voltage-gated potassium (Kv) channels, 62

W

Wakefulness test, 9
Warfarin, 64, 198
Wegener's granulomatosis, 118
Wheezing, 5, 95
Wnt pathway, 142
Wood's lamp, 96
World Health Organization meeting, 41, 43

X

Xanthines, 358

Z

Zebra, in medicine, 1–2